2-chloro-4-{[(3S)-1-(2-methylpropanoyl)-3-pyrrolidinyl]amino}benzonitrile | 1034856-25-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-4-{[(3S)-1-(2-methylpropanoyl)-3-pyrrolidinyl]amino}benzonitrile
• 英文别名: 2-chloro-4-[[(3S)-1-(2-methylpropanoyl)pyrrolidin-3-yl]amino]benzonitrile
• CAS: 1034856-25-1
• 化学式: C₁₅H₁₈ClN₃O
• 分子量: 291.78
• InChiKey: ZHINNQSOIMLLJJ-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  56.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-4-{[(3S)-1-(2-methylpropanoyl)-3-pyrrolidinyl]amino}benzonitrile 、 2-(三氟甲基)苄溴 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 生成 2-chloro-4-([(3S)-1-(2-methylpropanoyl)-3-pyrrolidinyl]([2-(trifluoromethyl)phenyl]methyl)amino)benzonitrile
  参考文献：
  名称：

  Improving the developability profile of pyrrolidine progesterone receptor partial agonists

  摘要：

  The previously reported pyrrolidine class of progesterone receptor partial agonists demonstrated excellent potency but suffered from serious liabilities including hERG blockade and high volume of distribution in the rat. The basic pyrrolidine amine was intentionally converted to a sulfonamide, carbamate, or amide to address these liabilities. The evaluation of the degree of partial agonism for these non-basic pyrrolidine derivatives and demonstration of their efficacy in an in vivo model of endometriosis is disclosed herein. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.092
• 作为产物：
  描述：

  2-chloro-4-[(3S)-3-pyrrolidinylamino]benzonitrile 、 异丁酰氯 以 二氯甲烷 为溶剂， 生成 2-chloro-4-{[(3S)-1-(2-methylpropanoyl)-3-pyrrolidinyl]amino}benzonitrile
  参考文献：
  名称：

  Improving the developability profile of pyrrolidine progesterone receptor partial agonists

  摘要：

  The previously reported pyrrolidine class of progesterone receptor partial agonists demonstrated excellent potency but suffered from serious liabilities including hERG blockade and high volume of distribution in the rat. The basic pyrrolidine amine was intentionally converted to a sulfonamide, carbamate, or amide to address these liabilities. The evaluation of the degree of partial agonism for these non-basic pyrrolidine derivatives and demonstration of their efficacy in an in vivo model of endometriosis is disclosed herein. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.092

文献信息

• WO2008/77089
  申请人：——

  公开号：——

  公开（公告）日：——
• PYRROLIDINANILINES
  申请人：Smithkline Beecham Corporation

  公开号：EP2094269A1

  公开（公告）日：2009-09-02
• [EN] PYRROLIDINANILINES<br/>[FR] PYRROLIDINANILINES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2008077089A1

  公开（公告）日：2008-06-26

  [EN] The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof where R¹, R², X, and y are defined herein. Compounds of the present invention are useful as progesterone receptor modulators.
  [FR] L'invention concerne un composé représenté par la formule (I) ou un sel pharmaceutiquement acceptable de celui-ci où R¹, R²